Jiang He, Yuan Feifei, Zhao Zhiying, Xue Tongchun, Ge Ningling, Ren Zhenggang, Zhang Lan
Department of Hepatic Oncology, Zhongshan Hospital, Liver Cancer Institute and Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Shanghai, People's Republic of China.
Int J Gen Med. 2021 Dec 1;14:9145-9152. doi: 10.2147/IJGM.S334378. eCollection 2021.
Ribosomal protein metallopanstimulin-1 (MPS-1) is implicated in tumorigenesis. However, to date, the underlying role of MPS-1 in the generation, progression and prognosis of hepatocellular carcinoma (HCC) remains unknown. This study aims to investigate the expression of MPS-1 in HCC and its significance for the prognosis of HCC.
The Oncomine and GEPIA databases were used to analyze the expression pattern of MPS-1 in HCC. Immunohistochemical staining was performed on tissue microarrays containing 169 HCC tissue samples to examine the expression of MPS-1. In addition, univariate and multivariate Cox regression analyses and Kaplan-Meier analysis were used to verify the correlation between clinicopathological factors in HCC patients and its clinical prognostic significance.
MPS-1 was more highly expressed in HCC than in normal tissues, and MPS-1 expression was correlated with serum AFP levels ( = 0.003), liver cirrhosis ( = 0.024), tumor embolus ( = 0.009) and tumor recurrence ( < 0.003). MPS-1 was an independent prognostic factor for the overall survival of HCC (HR, 1.92; 95% CI, 1.01-3.68), and a higher expression of MPS-1 predicted poorer survival. Furthermore, high expression of MPS-1 indicated a poor prognosis in patients with AFP positivity, cirrhosis or HBsAg positivity.
These findings demonstrate that MPS-1 is highly expressed in HCC and serves as an independent prognostic marker, highlighting the potential role of MPS-1 as a novel biomarker and therapeutic target for HCC.
核糖体蛋白金属全刺激素-1（MPS-1）与肿瘤发生有关。然而，迄今为止，MPS-1在肝细胞癌（HCC）的发生、发展和预后中的潜在作用仍不清楚。本研究旨在探讨MPS-1在HCC中的表达及其对HCC预后的意义。
利用Oncomine和GEPIA数据库分析MPS-1在HCC中的表达模式。对包含169例HCC组织样本的组织芯片进行免疫组织化学染色，以检测MPS-1的表达。此外，采用单因素和多因素Cox回归分析以及Kaplan-Meier分析来验证HCC患者临床病理因素之间的相关性及其临床预后意义。
MPS-1在HCC中的表达高于正常组织，且MPS-1表达与血清甲胎蛋白水平（=0.003）、肝硬化（=0.024）、肿瘤栓子（=0.009）和肿瘤复发（<0.003）相关。MPS-1是HCC总体生存的独立预后因素（HR，1.92；95%CI，1.01-3.68），MPS-1表达越高，预后越差。此外，MPS-1高表达表明甲胎蛋白阳性、肝硬化或乙肝表面抗原阳性患者预后不良。
这些发现表明MPS-1在HCC中高表达，可作为独立的预后标志物，突出了MPS-1作为HCC新型生物标志物和治疗靶点的潜在作用。
